MGI(SH:688114) Xin Lang Cai Jing·2025-10-13 10:30Core Insights - The company has signed a licensing agreement for the CoolMPS sequencing technology, which includes the transfer of related patents and revenue sharing with Swiss Rockets [1] Group 1: Licensing Agreement Details - The agreement involves the paid licensing of CoolMPS sequencing technology and related products to Swiss Rockets, which will receive exclusive rights outside the Asia-Pacific and Greater China regions [1] - The company expects to receive at least $120 million in licensing fees, including a non-refundable upfront payment of $20 million and milestone payments of $20 million [1] Group 2: Financial Impact - The upfront payment of $20 million will be recognized within the year, while the milestone payment will be made upon completion of technology transfer or by the end of 2026 [2] - Continuous royalty payments based on net sales of licensed products are expected to significantly improve the company's cash flow and profitability [2] Group 3: Strategic Focus and Market Expansion - The company aims to reduce overseas operational costs while focusing on high-end innovation and market expansion by transferring technology without engaging in product development [2] - The transaction allows the company to concentrate resources on its core technology and product development, enhancing overall resource utilization and operational efficiency [2] Group 4: Global Strategy and Market Position - The CoolMPS technology's overseas business development marks a new model for domestic high-end scientific instruments, leveraging local advantages of Swiss Rockets to accelerate global strategy [3] - The company retains autonomy in the Asia-Pacific and Greater China regions while expanding its international market presence, with international revenue accounting for over 30% [3] - Revenue projections for 2025-2027 are estimated at 3.585 billion, 4.184 billion, and 4.936 billion yuan, with corresponding net profits of 29 million, 104 million, and 219 million yuan [3]